Prof. Huaiqing Lv | Neck Tumors | Best Researcher Award

Posted on by Pencis

Prof. Huaiqing Lv | Neck Tumors | Best Researcher Award

Shandong Second Medical University | China

Author Profile

Scopus

šŸŒŸ Dr. Lv Huaiqing, M.D.

Chief Physician & Masterā€™s Degree Supervisor

Director of Otorhinolaryngology & Head and Neck Surgery

Linyi People’s Hospital, Shandong Province

šŸ‘©ā€āš•ļø Professional Summary:

Dr. Lv Huaiqing is a distinguished Chief Physician and subject leader at Linyi People’s Hospital, specializing in Otorhinolaryngology and Head and Neck Surgery. With extensive experience in clinical practice and research, Dr. Lv has significantly contributed to the field through her leadership roles and numerous scientific projects.

**šŸŒ Part-Time Roles:

  • Vice Chairman, Otorhinolaryngology, Head and Neck Surgery Committee, Shandong Provincial Medical Association
  • Vice Chairman, Hearing and Balance Medical Association, Shandong Provincial Medical Association
  • Member, Voice Committee, Otorhinolaryngology Committee, Chinese Association of Integrative Medicine
  • Standing Member, Head and Neck Tumor Committee, China Medical Education Association
  • Vice Chairman, Ear, Nose and Throat Committee, Shandong Association of Integrative Medicine
  • Vice Chairman, Pharyngeal, Head and Neck Surgery Committee, Shandong Provincial Association of Health Management
  • Director, Linyi Otorhinolaryngology Quality Control Center
  • Linyi Health Leader
  • Director, Otolaryngology Branch, Linyi Physicians Association

šŸ“š Research Contributions:

Dr. Lv has authored 13 papers as the first author or corresponding author in the past year. She has presided over 3 provincial and municipal level projects, including:

  • Application of Posterior Auricular Groove Incision in Surgery of Benign Tumor of Parotid Gland
  • Evaluation of Orbital Invasion of Sinus Tumor Based on CT, MRI, and Machine Learning Models
  • Posterior Auricular Groove Incision in Surgery of Benign Tumor of Superficial Parotid Gland

Her research has received significant funding of 400,000 RMB and has led to several municipal science and technology awards. The research team excels in various methods, including bioinformatics, meta-analysis, and machine learning predictive models.

šŸŽ“ Teaching Commitment:

Currently, Dr. Lv supervises Masterā€™s degree students at Qingdao University, Shandong Second Medical University, and Binzhou Medical College, having guided 10 students to date.

šŸ”¬ Current Publications:

She is also the first author or corresponding author of approximately 20 newly accepted and submitted articles in Chinese core or SCI journals.

Dr. Lv Huaiqingā€™s dedication to otorhinolaryngology, combined with her commitment to research and education, makes her a leading figure in her field.

šŸ”” Conclusion

Dr. Lv Huaiqing stands out as a prominent leader in Otorhinolaryngology and Head and Neck Surgery, with a rich background in clinical practice, research, and education. Her extensive involvement in various medical associations and committees demonstrates her commitment to advancing the field and enhancing patient care. Through her innovative research projects and dedication to mentoring future healthcare professionals, Dr. Lv continues to make significant contributions to medical science and the development of her specialty in Shandong Province and beyond.

šŸ“ŠšŸ”¬NOTABLE PUBLICATION:

    • Circ_0058124 upregulates MAPK1 expression to promote proliferation, metastasis and metabolic abilities in thyroid cancer through sponging miR-940
      • Authors: Sun, D., Chen, L., Lv, H., Liu, X., Zhang, X.
      • Journal: OncoTargets and Therapy
      • Year: 2020

     

    • Predicting biomarkers in laryngeal squamous cell carcinoma based on the cytokine-cytokine receptor interaction pathway
      • Authors: Chen, Q., Wang, D., Chen, Z., Li, P., Lv, H.
      • Journal: Heliyon
      • Year: 2024

     

    • Genetically predicted allergic rhinitis causally increases the risk of erectile dysfunction
      • Authors: Li, P., Meng, Z., Lin, L., Chen, Z., Lv, H.
      • Journal: Frontiers in Genetics
      • Year: 2024

     

    • A novel frameshift mutation of the endoglin (ENG) gene causes hereditary hemorrhagic telangiectasia in a Chinese family
      • Authors: Li, P., Gao, C., Wei, Y., Shao, Q., Lv, H.
      • Journal: European Archives of Oto-Rhino-Laryngology
      • Year: 2024

     

    • Upregulation of microRNA-141 suppresses epithelial-mesenchymal transition and lymph node metastasis in laryngeal cancer through HOXC6-dependent TGF-Ī² signaling pathway
      • Authors: Chen, L., Sun, D.-Z., Fu, Y.-G., Gao, Y., Zhang, X.-Y.
      • Journal: Cellular Signalling
      • Year: 2020

Dr. Lei Xia | Theranostics | Best Researcher Award

Posted on by Pencis

Dr. Lei Xia | Theranostics | Best Researcher Award

Peking University Cancer Hospital |Ā  China

Author Profile

Scopus

Orcid Id

Dr. Xia Lei, PhD šŸ§¬

Affiliation:
Department of Nuclear Medicine, Peking University Cancer Hospital
Physician, Associate Researcher

Contact Information:
šŸ“ž Phone: 18811177191
āœ‰ļø Email: xialei9012288@126.com

Biography:

Dr. Xia Lei, PhD, currently serves as a physician and associate researcher in the Department of Nuclear Medicine at Peking University Cancer Hospital. Dr. Lei graduated from the Medical School of Peking University in 2020. His expertise and research interests lie in the innovative field of nuclear medicine, particularly focusing on the development and clinical application of radiopharmaceutical probes for tumor targeting.

His primary research areas include:

  1. Construction of Tumor-Targeted Multimodal Imaging Molecular Probes šŸ©»
    • Dr. Lei is dedicated to creating advanced imaging probes that can target tumors with high precision, enhancing the accuracy of tumor detection and diagnosis.
  2. Development and Preliminary Application of Novel Integrated Diagnostic and Therapeutic Probes šŸ§«
    • He is pioneering the integration of diagnostic and therapeutic functions into single probes, aiming to streamline and improve the effectiveness of cancer treatment.
  3. Preparation and Clinical Translation of Tumor-Targeted Radiopharmaceutical Probes šŸ§Ŗ
    • Dr. Lei’s work involves preparing radiopharmaceuticals that specifically target tumors and translating these innovations from the lab to clinical settings to benefit patients.

Principal Investigator in Projects:

Dr. Lei has been the principal investigator for several prestigious projects, showcasing his leadership in research and innovation:

  1. National Natural Science Foundation of China, Young Scientists Fund (NO.82202201) šŸŒŸ
    • RMB 300,000 (January 2023 – December 2025)
  2. Young Talents Support Plan by the China Association for Science and Technology (NO. YESS20220230) šŸŒŸ
    • RMB 600,000 (January 2023 – December 2025)
  3. Beijing Natural Science Foundation, General Program (NO.7242266) šŸŒŸ
    • RMB 200,000 (January 2024 – December 2026)
  4. Peking University Cancer Hospital Science Innovation and Translation Fund šŸŒŸ
    • RMB 140,000 (January 2024 – December 2024)
  5. Medical School of Peking University, Young Scientists Innovation Fund šŸŒŸ
    • RMB 40,000
  6. Internal Fund of Peking University Cancer Hospital šŸŒŸ
    • RMB 80,000
  7. Peking University Cancer Hospital Science Innovation Nurturing Fund šŸŒŸ
    • RMB 100,000

Dr. Lei’s contributions to the field of nuclear medicine are instrumental in advancing the understanding and treatment of cancer, reflecting his commitment to medical innovation and patient care.

 

šŸ“ŠšŸ”¬Notable Publication:

 

 

 

 

Medical Oncology

Posted on by Pencis

Medical Oncology

Introduction to Medical Oncology: Medical Oncology is a specialized branch of medicine dedicated to the diagnosis, treatment, and management of cancer. This field plays a pivotal role in improving the lives of cancer patients through various treatment modalities and cutting-edge research. Within the realm of Medical Oncology, several key subtopics are essential for understanding and addressing the complexities of cancer care:

Chemotherapy and Targeted Therapies: Chemotherapy involves the use of drugs to kill or slow the growth of cancer cells, while targeted therapies focus on specific molecular abnormalities within cancer cells. Understanding these treatment options is crucial for medical oncologists to tailor therapies for individual patients.

Immunotherapy: Immunotherapy harnesses the body’s immune system to combat cancer. This groundbreaking approach has revolutionized cancer treatment by enhancing the body’s natural defenses against cancer cells.

Precision Medicine: Precision medicine in oncology involves customizing treatment plans based on a patient’s unique genetic and molecular profile. It allows for more personalized and effective cancer treatments, minimizing side effects.

Palliative Care: Palliative care in Medical Oncology is vital for improving the quality of life for cancer patients. It focuses on symptom management, pain relief, and emotional support to enhance patients’ overall well-being.

Clinical Trials and Research: Ongoing research and clinical trials are at the forefront of Medical Oncology. Investigating new treatments, therapies, and breakthroughs in cancer care is essential for improving patient outcomes and advancing the field.

These subtopics illustrate the multidimensional nature of Medical Oncology, where a comprehensive approach is taken to address the complexities of cancer treatment and patient care.